Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.47 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.47 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.47 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.47 |
| ▸ | CBFB | Q13951 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25914490 | 0.85 | MEN1 (0.50) | HDAC1SMN1; SMN2L3MBTL1HTTMEN1 | |
| SCHEMBL17802331 | 0.83 | RAB9A (0.46) | SMN1; SMN2HTTMEN1KMT2ANPC1 | |
| SCHEMBL30368269 | 0.82 | RAB9A (0.58) | HDAC1SMN1; SMN2L3MBTL1HTTMEN1 | |
| SCHEMBL27438068 | 0.82 | SMN1; SMN2 (0.54) | SMN1; SMN2L3MBTL1HTTMEN1KMT2A | |
| SCHEMBL863069 | 0.82 | RAB9A (0.58) | HDAC1SMN1; SMN2L3MBTL1HTTMEN1 | |
| SCHEMBL17813317 | 0.82 | SMN1; SMN2 (0.50) | SMN1; SMN2HTTMEN1KMT2AMAPT | |
| SCHEMBL8859960 | 0.81 | ALDH1A1 (0.55) | HDAC1MEN1KMT2AMAPTNPC1 | |
| SCHEMBL8251619 | 0.79 | NPC1 (0.62) | HDAC1SMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL13110612 | 0.79 | ALDH1A1 (0.57) | SMN1; SMN2L3MBTL1HTTMEN1KMT2A | |
| SCHEMBL30421453 | 0.79 | NPC1 (0.62) | HDAC1SMN1; SMN2HTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6624153-B2 | Derivatives of two synthetic anti-tuberculosis agents, thioacetazone and p-aminosalicylic acid, have been synthesized. In general, the halogenated compound has the structure of Structure I:for use as anti-tuberculosis | UNIVERSITY OF SCIENCES IN PHILADELPHIA | 2003-09-23 | — | — | US | disclosed |
| US-20030114531-A1 | Halogenated antituberculosis agents | KOBARFARD FARZAD (US) | 2003-06-19 | — | — | US | disclosed |
| WO-2002092019-A2 | HALOGENATED ANTITUBERCULOSIS AGENTS | UNIVERSITY OF THE SCIENCES IN PHILADELPHIA (US) | 2002-11-21 | — | — | WO | disclosed |
| US-20020173548-A1 | HALOGENATED ANTITUBERCULOSIS AGENTS | SCIENCES IN PHILADELPHIA, UNIVERSITY OF | 2002-11-21 | — | — | US | disclosed |
| US-6482982-B1 | BACTERICIDES; MYCOBACTERIUM RESISTANCE | UNIVERSITY OF SCIENCES OF PHILADELPHIA | 2002-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114531-A1 | Halogenated antituberculosis agents | XDH, TST, QSOX1 | HDAC1 1117/4885SMN1; SMN2 4853/4885L3MBTL1 1396/4885 |
| US-20020173548-A1 | HALOGENATED ANTITUBERCULOSIS AGENTS | XDH, TST, QSOX1 | HDAC1 1117/4885SMN1; SMN2 4853/4885L3MBTL1 1396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.